146 related articles for article (PubMed ID: 38832137)
1. Proton pump inhibitor
Oshima T
JGH Open; 2024 Jun; 8(6):e13104. PubMed ID: 38832137
[No Abstract] [Full Text] [Related]
2. Pathophysiology of Potassium-competitive Acid Blocker-refractory Gastroesophageal Reflux and the Potential of Potassium-competitive Acid Blocker Test.
Masaoka T; Kameyama H; Yamane T; Yamamoto Y; Takeuchi H; Suzuki H; Kitagawa Y; Kanai T
J Neurogastroenterol Motil; 2018 Oct; 24(4):577-583. PubMed ID: 30347936
[TBL] [Abstract][Full Text] [Related]
3. Use of vonoprazan, a novel potassium-competitive acid blocker, for the treatment of proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosis.
Shirai Y; Kawami N; Iwakiri K; Kuwana M
J Scleroderma Relat Disord; 2022 Feb; 7(1):57-61. PubMed ID: 35386943
[TBL] [Abstract][Full Text] [Related]
4. Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker.
Mori H; Suzuki H
J Neurogastroenterol Motil; 2019 Jan; 25(1):6-14. PubMed ID: 30504527
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.
Akiyama J; Hosaka H; Kuribayashi S; Moriyasu S; Hisada Y; Okubo H; Watanabe K; Imbe K; Nagata N; Kojima Y; Yokoi C; Uemura N; Shimoyama Y; Kawamura O; Yamada M; Kusano M
Digestion; 2020; 101(2):174-183. PubMed ID: 30897577
[TBL] [Abstract][Full Text] [Related]
6. Potassium-competitive acid blockers and gastroesophageal reflux disease.
Leowattana W; Leowattana T
World J Gastroenterol; 2022 Jul; 28(28):3608-3619. PubMed ID: 36161043
[TBL] [Abstract][Full Text] [Related]
7. Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
Okuyama M; Nakahara K; Iwakura N; Hasegawa T; Oyama M; Inoue A; Ishizu H; Satoh H; Fujiwara Y
Digestion; 2017; 95(4):281-287. PubMed ID: 28501868
[TBL] [Abstract][Full Text] [Related]
8. Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor: A Pilot Study on Comparable Efficacy in the Treatment of Gastroesophageal Reflux-Related Cough.
Zhong S; Zhong M; Fang L; Zhi H; Ji X; Tang K; Zhan C; Shi X; Xian M; Wang W; Li J; Luo W; Lai K; Chen R
Allergy Asthma Immunol Res; 2024 Mar; 16(2):191-201. PubMed ID: 38528386
[TBL] [Abstract][Full Text] [Related]
9. The Ameliorating Effect of Switching to Vonoprazan: A Novel Potassium-Competitive Acid Blocker in Patients with Proton Pump Inhibitor Refractory Non-Erosive Reflux Disease.
Abe Y; Koike T; Saito M; Okata T; Nakagawa K; Hatta W; Asanuma K; Uno K; Asano N; Imatani A; Masamune A
Digestion; 2021; 102(3):480-488. PubMed ID: 32062650
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of gastric endoscopic submucosal dissection without using proton pump inhibitor injection: a propensity score analysis.
Fushimi S; Horikawa Y; Mizutamari H; Mimori N; Kato Y; Sato S
J Rural Med; 2020 Jul; 15(3):85-91. PubMed ID: 32704333
[No Abstract] [Full Text] [Related]
11. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis.
Simadibrata DM; Syam AF; Lee YY
J Gastroenterol Hepatol; 2022 Dec; 37(12):2217-2228. PubMed ID: 36181401
[TBL] [Abstract][Full Text] [Related]
12. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date.
Sugano K
Therap Adv Gastroenterol; 2018; 11():1756283X17745776. PubMed ID: 29383028
[TBL] [Abstract][Full Text] [Related]
13. The pharmacotherapeutic management of gastroesophageal reflux disease (GERD).
Chapelle N; Ben Ghezala I; Barkun A; Bardou M
Expert Opin Pharmacother; 2021 Feb; 22(2):219-227. PubMed ID: 32893683
[TBL] [Abstract][Full Text] [Related]
14. Duodenal ulcer and gastroesophageal reflux disease today: long-term therapy--a sideways glance.
Bardhan KD
Yale J Biol Med; 1996; 69(3):211-24. PubMed ID: 9165690
[TBL] [Abstract][Full Text] [Related]
15. Tegoprazan to treat gastroesophageal reflux disease.
Mermelstein J; Mermelstein AC; Chait MM
Drugs Today (Barc); 2020 Nov; 56(11):715-721. PubMed ID: 33332479
[TBL] [Abstract][Full Text] [Related]
16. Effects of rikkunshito on quality of life in patients with gastroesophageal reflux disease refractory to proton pump inhibitor therapy.
Kawai T; Hirayama Y; Oguchi A; Ishii F; Matushita M; Kitayama N; Morishita S; Hiratsuka N; Ohata K; Konishi H; Kishino M; Nakamura S
J Clin Biochem Nutr; 2017 Mar; 60(2):143-145. PubMed ID: 28366995
[TBL] [Abstract][Full Text] [Related]
17. Treatment Strategy for Standard-Dose Proton Pump Inhibitor-Resistant Reflux Esophagitis.
Iwakiri K
J Nippon Med Sch; 2017; 84(5):209-214. PubMed ID: 29142181
[TBL] [Abstract][Full Text] [Related]
18. Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease.
Miwa H; Igarashi A; Teng L; Uda A; Deguchi H; Tango T
J Gastroenterol; 2019 Aug; 54(8):718-729. PubMed ID: 30919071
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of a potassium-competitive acid blocker for improving symptoms in patients with reflux esophagitis, non-erosive reflux disease, and functional dyspepsia.
Asaoka D; Nagahara A; Hojo M; Matsumoto K; Ueyama H; Matsumoto K; Izumi K; Takeda T; Komori H; Akazawa Y; Shimada Y; Osada T; Watanabe S
Biomed Rep; 2017 Feb; 6(2):175-180. PubMed ID: 28357069
[TBL] [Abstract][Full Text] [Related]
20. Relationship between long-term use of proton pump inhibitor (PPI) and hypomagnesemia in patients with gastroesophageal reflux disease.
Arj A; Ghaleh Takizadeh Z; Gilassi H; Razavizadeh M
Caspian J Intern Med; 2022; 13(1):107-112. PubMed ID: 35178215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
